Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab
Clinical and Experimental Nephrology · 2024
DOI: 10.1007/s10157-024-02484-9 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical and Experimental Nephrology, 2024. Verfasst von Yusuke Gonda und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama, 330-8777, Japan. Hauptthemen laut MEDLINE: Rituximab, Nephrotic Syndrome, Immunosuppressive Agents, Remission Induction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama, 330-8777, Japan.
- Department of Pediatrics, Juntendo University Urayasu Hospital, Chiba, Japan.
- Division of Nephrology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama, 330-8777, Japan. f_shuich@d2.dion.ne.jp.
Zitieren
APA
Gonda, Y., & Fujinaga, S. (2024). Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02484-9
Vancouver
Gonda Y, Fujinaga S. Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab. Clinical and Experimental Nephrology. 2024. doi:10.1007/s10157-024-02484-9
BibTeX
@article{Gonda2024,
author = {Gonda, Yusuke and Fujinaga, Shuichiro},
title = {Optimal course of pre-emptive rituximab administration for long-term disease remission in patients with complicated steroid-dependent nephrotic syndrome requiring immunosuppressive agents after rituximab},
journal = {Clinical and Experimental Nephrology},
year = {2024},
doi = {10.1007/s10157-024-02484-9}
}
EUVIMED